Suvorexant, FDA-approved to treat insomnia, has demonstrated efficacy in helping patients with insomnia improve their ability to fall asleep and remain asleep (Table 1).1 This first-in-class compound represents a novel mechanism of action to promoting sleep that may avoid some problems associated with other hypnotics.2.
|Original language||English (US)|
|Number of pages||6|
|State||Published - 2015|
ASJC Scopus subject areas
- Psychiatry and Mental health